A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products
Key News
SEPTEMBER 18, 2023
Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose
SEPTEMBER 5, 2023
Orexo to present at Pareto Securities 14th Annual Healthcare Conference
AUGUST 31, 2023
International Overdose Awareness Day: Why are so many people dying?
To read all NEWS go to Media in the top menu
Key financial figures
Group net revenue
634 MSEK
Last Twelve Months, Q322-Q223
Group EBITDA
-121 MSEK
Last Twelve Months, Q322-Q223
US Pharma segment EBIT
293 MSEK
Last Twelve Months, Q322-Q223
Cash position
251 MSEK
Q223